Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Francis Giles*, David Rizzieri, Farhad Ravandi, Ronan Swords, Tove Flem Jacobsen, Susan O'Brien

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

15 Scopus citations
Original languageEnglish (US)
Pages (from-to)e71-e73
JournalLeukemia Research
Volume36
Issue number4
DOIs
StatePublished - Apr 1 2012

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this